{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:21:25Z","timestamp":1790014885144,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-00154"],"award-info":[{"award-number":["2021-00154"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Hypothesis<\/jats:title>\n                  <jats:p>There is a paucity of research on treatment outcomes of patients with psychosis and cannabis use disorder (CUD). We aimed to compare the effectiveness of antipsychotics in reducing the risk of hospitalization in patients with first-episode psychosis (FEP) and co-occurring CUD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>We utilized a nationwide Swedish cohort of patients with longitudinal register data from the year 2006 to 2021. Participants were patients with FEP and co-occurring CUD (n\u2005=\u20051820, 84.73% men, mean age 26.80 years, SD 8.25 years). The main outcome was hospitalization due to psychotic relapse. Hospitalization due to any psychiatric disorder or substance use disorder (SUD) were examined as secondary outcomes. Within-individual Cox regression models were used to study these associations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Results<\/jats:title>\n                  <jats:p>Use of any antipsychotic was associated with a 33% risk reduction of psychotic relapse (aHR\u2005=\u20050.67; 95% CI 0.60\u20130.75). Clozapine (0.43; 0.29\u20130.64), long-acting injectable (LAI) formulations of risperidone (0.40; 0.22\u20130.71), aripiprazole (0.42; 0.27\u20130.65), and paliperidone (0.46; 0.30\u20130.69) were associated with the lowest risk of relapse. The association between the LAI formulation of olanzapine and hospitalization due to psychosis was statistically non-significant (0.61; 0.35\u20131.05). Clozapine was associated with an 86% risk reduction of hospitalization due to SUD (0.14; 0.05\u20130.44). Of oral non-clozapine antipsychotics, aripiprazole was associated with the lowest risk of hospitalization due to psychotic relapse (0.61; 0.45\u20130.83).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings support the use of clozapine, LAI formulations of second-generation antipsychotics other than olanzapine, or oral aripiprazole to prevent hospitalization in FEP and co-occurring CUD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbae034","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T15:56:03Z","timestamp":1711554963000},"page":"1287-1294","source":"Crossref","is-referenced-by-count":12,"title":["Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study"],"prefix":"10.1093","volume":"50","author":[{"given":"Alexander","family":"Denissoff","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Turku , Turku ,","place":["Finland"]},{"name":"Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, The Wellbeing Services County of Southwest Finland , Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"School of Pharmacy, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Di Forti","sequence":"additional","affiliation":[{"name":"Department of Social Genetics and Developmental Psychiatry, IoPPN, King\u2019s College London , London ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-0721","authenticated-orcid":false,"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-3126","authenticated-orcid":false,"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio ,","place":["Finland"]},{"name":"Department of Clinical Neuroscience, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-2122","authenticated-orcid":false,"given":"Antti","family":"Mustonen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, Tampere University , Tampere ,","place":["Finland"]},{"name":"Department of Psychiatry, Sein\u00e4joki Central Hospital , Sein\u00e4joki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solja","family":"Niemel\u00e4","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Turku , Turku ,","place":["Finland"]},{"name":"Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, The Wellbeing Services County of Southwest Finland , Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"3","key":"2024112102160091500_CIT0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0004867415599846","article-title":"Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use","volume":"50","author":"Myles","year":"2015","journal-title":"Aust N Z J Psychiatry."},{"key":"2024112102160091500_CIT0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2017.06.039","article-title":"Demographic and clinical correlates of substance use disorders in first episode psychosis","volume":"194","author":"Brunette","year":"2018","journal-title":"Schizophr Res."},{"issue":"6","key":"2024112102160091500_CIT0003","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.eurpsy.2011.03.001","article-title":"Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis","volume":"27","author":"Schimmelmann","year":"2012","journal-title":"Eur Psychiatry."},{"key":"2024112102160091500_CIT0004","doi-asserted-by":"crossref","first-page":"107919","DOI":"10.1016\/j.drugalcdep.2020.107919","article-title":"Substance use disorders before, at and after first episode psychosis hospitalizations in a young national Swedish cohort","volume":"209","author":"Str\u00e5lin","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"2024112102160091500_CIT0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/schbul\/sbad033","article-title":"Cannabis use and symptomatic relapse in first episode schizophrenia: trigger or consequence? Data from the OPTIMISE Study","volume":"49","author":"Levi","year":"2023","journal-title":"Schizophr Bull."},{"key":"2024112102160091500_CIT0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2019.11.025","article-title":"Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia","volume":"225","author":"Emsley","year":"2020","journal-title":"Schizophr Res."},{"issue":"14","key":"2024112102160091500_CIT0007","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0033291717000976","article-title":"Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes","volume":"47","author":"Ouellet-Plamondon","year":"2017","journal-title":"Psychol Med."},{"key":"2024112102160091500_CIT0008","doi-asserted-by":"crossref","first-page":"114022","DOI":"10.1016\/j.psychres.2021.114022","article-title":"Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment","volume":"302","author":"Scheffler","year":"2021","journal-title":"Psychiatry Res."},{"issue":"4","key":"2024112102160091500_CIT0009","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/acps.13081","article-title":"Stopping cannabis use benefits outcome in psychosis: findings from 10-year follow-up study in the PAFIP-cohort","volume":"140","author":"Seti\u00e9n-Suero","year":"2019","journal-title":"Acta Psychiatr Scand."},{"issue":"8","key":"2024112102160091500_CIT0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2215-0366(17)30233-X","article-title":"Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis","volume":"4","author":"Schoeler","year":"2017","journal-title":"Lancet Psychiatry."},{"issue":"11","key":"2024112102160091500_CIT0011","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2016.2427","article-title":"Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study","volume":"73","author":"Schoeler","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"3","key":"2024112102160091500_CIT0012","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/schbul\/sbp126","article-title":"Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use","volume":"37","author":"Gonz\u00e1lez-Pinto","year":"2011","journal-title":"Schizophr Bull."},{"key":"2024112102160091500_CIT0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2022.02.026","article-title":"Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia","volume":"243","author":"Bioque","year":"2022","journal-title":"Schizophr Res."},{"issue":"6","key":"2024112102160091500_CIT0014","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/acps.13562","article-title":"Does a history of cannabis use influence onset and course of schizophrenia","volume":"147","author":"Allebeck","year":"2023","journal-title":"Acta Psychiatr Scand."},{"issue":"3","key":"2024112102160091500_CIT0015","doi-asserted-by":"crossref","first-page":"e009888","DOI":"10.1136\/bmjopen-2015-009888","article-title":"Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study","volume":"6","author":"Patel","year":"2016","journal-title":"BMJ Open."},{"key":"2024112102160091500_CIT0016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.psychres.2018.08.005","article-title":"Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: a 6-year follow-up in an inpatient cohort","volume":"268","author":"Colizzi","year":"2018","journal-title":"Psychiatry Res."},{"issue":"5","key":"2024112102160091500_CIT0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1192\/bjp.2019.120","article-title":"Clinical indicators of treatment-resistant psychosis","volume":"216","author":"Legge","year":"2020","journal-title":"Br J Psychiatry."},{"issue":"6","key":"2024112102160091500_CIT0018","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1192\/bjp.2022.117","article-title":"Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts","volume":"221","author":"L\u00e4hteenvuo","year":"2022","journal-title":"Br J Psychiatry."},{"issue":"1","key":"2024112102160091500_CIT0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2018.11.1105","article-title":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis","volume":"29","author":"Krause","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"issue":"11","key":"2024112102160091500_CIT0020","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S2215-0366(22)00304-2","article-title":"The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis","volume":"9","author":"Leucht","year":"2022","journal-title":"Lancet Psychiatry."},{"issue":"2","key":"2024112102160091500_CIT0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/02698811221142575","article-title":"Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: a systematic review and meta-analysis","volume":"37","author":"Rafizadeh","year":"2023","journal-title":"J Psychopharmacol."},{"issue":"1\u20132","key":"2024112102160091500_CIT0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"J Dual Diagn."},{"issue":"3","key":"2024112102160091500_CIT0023","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psychres.2011.05.001","article-title":"Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes","volume":"188","author":"Sevy","year":"2011","journal-title":"Psychiatry Res."},{"issue":"3","key":"2024112102160091500_CIT0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"Am J Addict."},{"issue":"1","key":"2024112102160091500_CIT0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull."},{"issue":"21","key":"2024112102160091500_CIT0026","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality","volume":"367","author":"Lichtenstein","year":"2012","journal-title":"N Engl J Med."},{"key":"2024112102160091500_CIT0027","volume-title":"MiDAS: Sjukpenning och Rehabiliteringspenning Version 1.02 (in Swedish) [MiDAS: Sickness Benefit and Rehabilitation Allowance]","author":"\u00d6sterlund","year":"2011"},{"issue":"1","key":"2024112102160091500_CIT0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods\u2014a second generation method (PRE2DUP)","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak."},{"issue":"1","key":"2024112102160091500_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health."},{"key":"2024112102160091500_CIT0030","doi-asserted-by":"crossref","DOI":"10.4135\/9781412993869","volume-title":"Fixed Effects Regression Models","author":"Allison","year":"2009"},{"issue":"6","key":"2024112102160091500_CIT0031","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"2024112102160091500_CIT0032","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry."},{"issue":"6","key":"2024112102160091500_CIT0033","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry."},{"key":"2024112102160091500_CIT0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2017.03.030","article-title":"Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: a randomized fMRI study","volume":"194","author":"Machielsen","year":"2018","journal-title":"Schizophr Res."},{"issue":"4","key":"2024112102160091500_CIT0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/sbl003","article-title":"Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders","volume":"32","author":"Brunette","year":"2006","journal-title":"Schizophr Bull."},{"issue":"5","key":"2024112102160091500_CIT0036","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry."},{"issue":"2","key":"2024112102160091500_CIT0037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull."},{"issue":"1","key":"2024112102160091500_CIT0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry."},{"issue":"5","key":"2024112102160091500_CIT0039","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry."},{"key":"2024112102160091500_CIT0040","doi-asserted-by":"crossref","first-page":"769623","DOI":"10.3389\/fpsyt.2021.769623","article-title":"Partial agonists and dual disorders: focus on dual schizophrenia","volume":"12","author":"Peris","year":"2021","journal-title":"Front Psychiatry."},{"issue":"6","key":"2024112102160091500_CIT0041","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","article-title":"Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence","volume":"37","author":"Beresford","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"2024112102160091500_CIT0042","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/NDT.S171002","article-title":"Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life","volume":"14","author":"Cuomo","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"9896","key":"2024112102160091500_CIT0043","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet (London, England)."},{"issue":"6","key":"2024112102160091500_CIT0044","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"issue":"7","key":"2024112102160091500_CIT0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"\u00c1lvarez-Jim\u00e9nez","year":"2008","journal-title":"CNS Drugs."},{"issue":"1","key":"2024112102160091500_CIT0046","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res."},{"issue":"2","key":"2024112102160091500_CIT0047","first-page":"125","article-title":"Comparison of data sources on alcohol problems: an exploratory exercise using surveys vs. national healthcare registers. NAD Nord Stud Alcohol Drugs","volume":"38","author":"M\u00e4kel\u00e4","year":"2021","journal-title":"Nordisk alkohol- & narkotikatidskrift."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/50\/6\/1287\/60774321\/sbae034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/50\/6\/1287\/60774321\/sbae034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T02:16:26Z","timestamp":1732155386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/50\/6\/1287\/7635752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae034","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,3,26]]}}}